A.R.T. Advisors’s Palvella Therapeutics PVLA Stock Holding History

A.R.T. Advisors’s Portfolio PVLA Stock Details PVLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-591	Closed	-$171K	–	1035
2019 Q4	$171K	Buy	+591	New	+$164K	0.01%	1177
2019 Q3	–	Sell	-223	Closed	-$84K	–	1775
2019 Q2	$84K	Buy	+223	New	+$66.5K	﹤0.01%	1215
2019 Q1	–	Sell	-146	Closed	-$31K	–	1671
2018 Q4	$31K	Buy	+146	New	+$45.3K	﹤0.01%	1234
2018 Q2	–	Sell	-189	Closed	-$103K	–	1806
2018 Q1	$103K	Buy	+189	New	+$117K	﹤0.01%	1353

Other funds holding PVLA

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

ACM

Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Corriente Advisors Fort Worth, Texas $9.53M AUM 805.26% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

TCM

Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

A.R.T. Advisors's PVLA Position: Q1 2020 in Review

A.R.T. Advisors sold out of Palvella Therapeutics (PVLA) in Q1 2020, closing a stake of 591 shares — an estimated $171K sold.

A.R.T. Advisors first reported a position in PVLA in Q1 2018 and held it in 4 quarters. The position peaked at $171K in Q4 2019. 95 funds tracked by Wall St. Rank hold PVLA as of Q1 2020.

A.R.T. Advisors reported no remaining Palvella Therapeutics position as of Q1 2020 after selling out during the quarter.
A.R.T. Advisors sold 591 Palvella Therapeutics shares in Q1 2020, an estimated $171K.
A.R.T. Advisors first reported a position in Palvella Therapeutics in Q1 2018 and held it in 4 quarters.
A.R.T. Advisors's Palvella Therapeutics position peaked at $171K in Q4 2019.
95 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q1 2020.

Based on A.R.T. Advisors's 13F filing for Q1 2020, filed 15 May 2020.